CAW
VNDA icon

Cornerstone Advisors (Washington)’s Vanda Pharmaceuticals VNDA Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-44
Closed -$1K – 821
2019
Q4 		$1K Hold
44
– – ﹤0.01% 729
2019
Q3 		$1K Sell
44
-16
-27% -$223 ﹤0.01% 719
2019
Q2 		$1K Buy
+60
New +$955 ﹤0.01% 1417

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Cornerstone Advisors (Washington)'s VNDA Position: Q1 2020 in Review

Cornerstone Advisors (Washington) sold out of Vanda Pharmaceuticals (VNDA) in Q1 2020, closing a stake of 44 shares — an estimated $1K sold.

Cornerstone Advisors (Washington) first reported a position in VNDA in Q2 2019 and held it in 3 quarters. The position peaked at $1K in Q4 2019. 159 funds tracked by Wall St. Rank hold VNDA as of Q1 2020.

  • Cornerstone Advisors (Washington) reported no remaining Vanda Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Cornerstone Advisors (Washington) sold 44 Vanda Pharmaceuticals shares in Q1 2020, an estimated $1K.
  • Cornerstone Advisors (Washington) first reported a position in Vanda Pharmaceuticals in Q2 2019 and held it in 3 quarters.
  • Cornerstone Advisors (Washington)'s Vanda Pharmaceuticals position peaked at $1K in Q4 2019.
  • 159 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2020.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q1 2020, filed 22 Apr 2020.